Low-risk group patients exhibited an immune-favorable microenvironment and were more abundant with activated CD56 bright NK, γδ-T, and Th17 cells, higher tumor mutational burden (TMB), and elevated CTLA-4 expression, which were likely associated with improved response to immune checkpoint inhibitors (ICIs). The gene discussed is NCAM1; the disease is neoplasm.